TUCSON
520.748.4400
About Us
Professional Staff
Board of Directors
Careers
Contact Us
Frederick Gardner
Cottrell Foundation
Successes
Ventures
Biotechnology
Medical Devices
Other
Historic Investments
Technologies
The CH2 Domain Scaffold – ABDURINS™
Deimmunized Sarcin Ribotoxin
Endotoxin-free ClearColi™ Expression System
Fibronectin Artificial Antibody Scaffold
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
Pichia Classic Expression Platform
Pichia GlyoSwitch™ Protein Expression System
Shingles Vaccine Antigen
Ultrasound Tissue Harmonic Imaging
VIMPAT® (lacosamide) for Treatment of Epileptic Seizures
Innovate With Us
News & Events
Home
»
News & Events
»
2012
BioCision Raises $2.5 Million Growth Financing to Support Continued Expansion
12.4.2012
UCB Commences Phase 3 Lacosamide Study in Asia
11.19.2012
Pichia-manufactured Jetrea® Approved by FDA for the Treatment of Symptomatic Vitreomacular Adhesion
10.18.2012
Option 3’s Laproscopic Fascial Closure System Awarded Innovation of the Year
8.28.2012
Esperance Pharmaceuticals Completes Run-in Enrollment of Phase 2 Clinical Trial of EP-100
8.28.2012
RCT demonstrates long half-life of CH2 domains
7.11.2012
RCT partners with Isogenica for large-scale screening of CH2 domains
7.11.2012
Esperance Pharmaceuticals Initiates Phase 2 Clinical Trial of EP-100
5.17.2012
Teleflex Acquires Option 3’s Laparoscopic Fascial Closure System
5.1.2012
News by Year
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
From concept
to market
Innovate with us ›